Detalles de la búsqueda
1.
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
J Intern Med
; 293(5): 648-655, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843323
2.
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
J Intern Med
; 292(3): 477-491, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411981
3.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
JAMA
; 326(23): 2375-2384, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932077
4.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
JAMA
; 325(17): 1744-1754, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33944876
5.
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Lancet Rheumatol
; 6(4): e226-e236, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402891
6.
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
BioDrugs
; 36(6): 731-748, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36315391
Resultados
1 -
6
de 6
1
Próxima >
>>